Analysis of guideline recommended use of renal mass biopsy and association with treatment
Joaquin Michel1, Andrew T. Lenis1, Patrick M. Lec1, Vishnukam Golla1, David C. Johnson2, Kiran Gollapudi3, Jeremy Blumberg3, Brian M. Shuch1,4, Karim Chamie1,4
Canadian Journal of Urology, Vol.27, No.4, pp. 10285-10293, 2020
Abstract Introduction: Renal mass biopsy (RMB) may not be indicated when the results are unlikely to impact management, such as in young and/or healthy patients and in elderly and/or frail patients. We analyzed the utility of RMB in three patient cohorts stratified by age-adjusted Charlson comorbidity index score (ACCI).
Materials and methods: We identified patients with cT1a renal tumors in the National Cancer Database from 2004-2014. We combined age and Charlson-Deyo scores to identify young and/or healthy patients (“healthy-ACCI”), elderly and/or frail patients (“frail-ACCI”), and a reference cohort. We performed multivariable logistic regression to identify predictors of RMB… More >